Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 21:2018:6727421.
doi: 10.1155/2018/6727421. eCollection 2018.

Peroxisome Proliferator-Activated Receptor γ and PGC-1 α in Cancer: Dual Actions as Tumor Promoter and Suppressor

Affiliations
Review

Peroxisome Proliferator-Activated Receptor γ and PGC-1 α in Cancer: Dual Actions as Tumor Promoter and Suppressor

Seong-Hoon Yun et al. PPAR Res. .

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is part of a nuclear receptor superfamily that regulates gene expression involved in cell differentiation, proliferation, immune/inflammation response, and lipid metabolism. PPARγ coactivator-1α (PGC-1α), initially identified as a PPARγ-interacting protein, is an important regulator of diverse metabolic pathways, such as oxidative metabolism and energy homeostasis. The role of PGC-1α in diabetes, neurodegeneration, and cardiovascular disease is particularly well known. PGC-1α is also now known to play important roles in cancer, independent of the role of PPARγ in cancer. Though many researchers have studied the expression and clinical implications of PPARγ and PGC-1α in cancer, there are still many controversies about the role of PPARγ and PGC-1α in cancer. This review examines and summarizes some recent data on the role and action mechanisms of PPARγ and PGC-1α in cancer, respectively, particularly the recent progress in understanding the role of PPARγ in several cancers since our review was published in 2012.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of PPARγ (a) and the PGC-1 family (b). (a) A/B, transcriptional activation domain; C, DNA binding domain (DBD); D, hinge region; E/F, ligand binding domain (LBD). (b) AD, transcriptional activation domain; RD, transcriptional repression domain; RS, arginine/serine rich domain; RRM, RNA binding domain.
Figure 2
Figure 2
Action mechanisms of PPARγ as a tumor suppressor. NF-κB, nuclear factor-κB; GSK-3β, glycogen synthase kinase 3-β; MUC1-C, mucin 1-C; TERT, telomerase reverse transcriptase; STAT5, signal transducer and activator of transcription factor 5; HIF-2α, hypoxia inducible factor-2α; IL-6, interleukin-6; PDK1, pyruvate dehydrogenase kinase 1.
Figure 3
Figure 3
Action mechanisms of PPARγ as a tumor promoter. ACLY, ATP citrate lyase; MIG12, midline-1-interacting G12-like protein; FASN, fatty acid synthase; NR1D1, Rev-ErbAα; KLF4, Krüppel-Like Factor 4; ALDH, aldehyde dehydrogenase; Nox1, NADPH oxidase 1; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.

References

    1. Mangelsdorf D. J., Thummel C., Beato M., et al. The nuclear receptor super-family: the second decade. Cell. 1995;83(6):835–839. doi: 10.1016/0092-8674(95)90199-X. - DOI - PMC - PubMed
    1. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochimica et Biophysica Acta—Lipids and Lipid Metabolism. 1996;1302(2):93–109. doi: 10.1016/0005-2760(96)00066-5. - DOI - PubMed
    1. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R. The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry. 2000;43(4):527–550. doi: 10.1021/jm990554g. - DOI - PubMed
    1. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes & Development. 1994;8(10):1224–1234. doi: 10.1101/gad.8.10.1224. - DOI - PubMed
    1. Fajas L., Auboeuf D., Raspé E., et al. The organization, promoter analysis, and expression of the human PPARγ gene. The Journal of Biological Chemistry. 1997;272(30):18779–18789. doi: 10.1074/jbc.272.30.18779. - DOI - PubMed